Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

OBJECTIVE: Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double–blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Leurent, Claire, Goodman, James A., Zhang, Yao, He, Ping, Polimeni, Jonathan R., Gurol, Mahmut Edip, Lindsay, Monica, Frattura, Linda, Sohur, Usharbudh Shivraj, Viswanathan, Anand, Bednar, Martin M., Smith, Eric E., Greenberg, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469253/
https://www.ncbi.nlm.nih.gov/pubmed/31020004
http://dx.doi.org/10.1002/acn3.761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469253/
https://www.ncbi.nlm.nih.gov/pubmed/31020004
http://dx.doi.org/10.1002/acn3.761

Ejemplares similares